This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horn, E. M. Articles by Bilezikian, J. P. Search for Related Content PubMed PubMed Citation Articles by Horn, E. M. Articles by Bilezikian, J. P.

Circulation, Vol 78, 1373-1379, Copyright © 1988 by American Heart Association

ARTICLES

Reduced lymphocyte stimulatory guanine nucleotide regulatory protein and beta-adrenergic receptors in congestive heart failure and reversal with angiotensin converting enzyme inhibitor therapy

EM Horn, SJ Corwin, SF Steinberg, YK Chow, GW Neuberg, PJ Cannon, ER Powers and JP Bilezikian
Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032.

Adrenergic hyporesponsiveness in congestive heart failure has been understood previously in terms of a reduction in beta-adrenergic receptors. We have examined another hypothesis, one that states the stimulatory guanine nucleotide regulatory protein (Gs) that couples the beta-adrenergic receptor to adenylate cyclase activity is also decreased in congestive heart failure. In addition to the 40% decrease in lymphocyte beta-adrenergic receptors in patients in congestive heart failure (5.9 +/- 0.7 vs. 9.7 +/- 1.4 fmol/mg, p less than 0.05), we found an 80% decrease in levels of Gs compared with age- and sex- matched healthy control subjects (72.5 +/- 19 vs. 376 +/- 73 fmol/mg, p less than 0.05). Myocardial Gs levels correlated significantly with lymphocyte Gs levels. We also assessed the hypothesis that reductions in beta-adrenergic receptors and in Gs are reversible after successful therapy with angiotensin converting enzyme inhibitors. Treatment with either captopril or lisinopril was associated with clinical improvement, an increase in beta-adrenergic receptor density (from 5.5 +/- 0.7 to 8.7 +/- 1.5 fmol/mg), and a twofold increase in Gs levels (p less than 0.05). Thus, the data are compatible with Gs serving as an adaptable and reversible regulator of the adrenergic response in congestive heart failure. In view of the fact that Gs is a transducing element common to all hormones that stimulate cyclic adenosine 5'- monophosphate production, the observations could extend to other abnormal neurohumoral mechanisms in congestive heart failure.

This article has been cited by other articles:

				X. Wang, E. Sentex, D. Chapman, and N. S. Dhalla Alterations of adenylyl cyclase and G proteins in aortocaval shunt-induced heart failure Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H118 - H125. [Abstract] [Full Text] [PDF]

				N. Dzimiri Regulation of beta -Adrenoceptor Signaling in Cardiac Function and Disease Pharmacol. Rev., September 1, 1999; 51(3): 465 - 502. [Abstract] [Full Text] [PDF]

				N. Fujii, S. Homma, F. Yamazaki, R. Sone, T. Shibata, H. Ikegami, K. Murakami, and H. Miyazaki beta -Adrenergic receptor number in human lymphocytes is inversely correlated with aerobic capacity Am J Physiol Endocrinol Metab, June 1, 1998; 274(6): E1106 - E1112. [Abstract] [Full Text] [PDF]

				A. K. Laflamme, L. Oster, R. Cardinal, and J. de Champlain Effects of Renin-Angiotensin Blockade on Sympathetic Reactivity and ß-Adrenergic Pathway in the Spontaneously Hypertensive Rat Hypertension, August 1, 1997; 30(2): 278 - 287. [Abstract] [Full Text]

				N. Fujii, T. Shibata, S. Homma, H. Ikegami, K. Murakami, and H. Miyazaki Exercise-induced changes in beta -adrenergic-receptor mRNA level measured by competitive RT-PCR J Appl Physiol, June 1, 1997; 82(6): 1926 - 1931. [Abstract] [Full Text] [PDF]

				J. D. Sackner-Bernstein and D. M. Mancini Rationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade JAMA, November 8, 1995; 274(18): 1462 - 1467. [Abstract] [PDF]

				R.D. Feldman, C.M. Tan, and J. Chorazyczewski G Protein Alterations in Hypertension and Aging Hypertension, November 1, 1995; 26(5): 725 - 732. [Abstract] [Full Text]

				P. J. Mills, J. E. Dimsdale, M. G. Ziegler, and R. A. Nelesen Racial Differences in Epinephrine and ß2-Adrenergic Receptors Hypertension, January 1, 1995; 25(1): 88 - 91. [Abstract] [Full Text]